Rho signaling in vascular diseases

Molecular Interventions

Volumn 4, Issue 6, 2004, Pages 348-357

  Seasholtz, Tammy M ^a   Brown, Joan Heller ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; NITRIC OXIDE SYNTHASE; PROTEIN KINASE (CALCIUM,CALMODULIN); RHO FACTOR; RHO KINASE; RHO KINASE INHIBITOR; SPHINGOSINE 1 PHOSPHATE; THROMBIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG TARGETING; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN BINDING; RAT; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

CELL PROLIFERATION; GENE EXPRESSION; HUMANS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 12344329603     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.4.6.8     Document Type: Review

References (108)

1. Seasholtz, T.M., Majumdar, M., Kaplan, D.D., and Brown, J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ. Res. 84, 1186-1193 (1999).
2. Sander, E.E. and Collard, J.G. Rho-like GTPases: Their role in epithelial cell-cell adhesion and invasion. Eur. J. Cancer 35 1302-1308 (1999).
3. Majumdar, M., Seasholtz, T.M., Goldstein, D., de Lanerolle, P., and Brown, J.H. Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis. J. Biol. Chem. 273, 10099-10106 (1998).
4. Sauzeau, V., Le Mellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P., and Loirand, G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho kinase. Circ. Res. 88, 1102-1104 (2001).
5. Treisman, R., Alberts, A.S., and Sahai, E. Regulation of SRF activity by Rho family GTPases. Cold Spring Harb. Symp. Quant. Biol. 63, 643-651 (1998).
6. Morissette, M. R., Sah, V.P., Glembotski, C.C., and Brown, J.H. The Rho effector, PKN, regulates ANF gene transcription in cardiomyocutes through a serum response element. Am. J. Physiol. 278, H1769-H1774 (2000).
7. Fritz, G and Kaina, B. Transcriptional activation of the small GTPase gene RhoB by genotoxic stress is regulated via a CCAAT element. Nucleic Acids Res. 29, 792-798 (2001).
8. Chen, Z., Sun, J., Pradines, A., Favre, G., Adnane, J., and Sebti, S.M. Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. J. Biol. Chem. 275, 17974-17978 (2000).
9. Suwa, H., Ohshio, G., Imamura, T., Watanabe, G., Arii, S., Imamura, M., Narumiya, S., Hiai, H., and Fukumoto, M. Overexpression of the rhoC gene correlates with progression of duodenal adenocarcinoma of the pancreas. Br. J. Cancer 77, 147-152 (1998).
10. van Golen, K.L., Davies, S., Wu, Z.F. et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin. Cancer Res. 5, 2511-2519 (1999).
11. Ren, X.D., Kiosses, W. B., and Schwartz, M. A. Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J. 18, 578-585 (1999).
12. Dubreuil, C. I., Winton, M.J., and McKerracher, L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J. Cell Biol. 162, 233-243 (2003).
13. Yoshizaki, H., Ohba, Y., Kurokawa, K., Itoh, R.E., Nakamura, T, Mochizuchi, N., Nagashima, K., and Matsuda, M. Activity of Rho-family GTPases during cell division as visualized with FRET-based probes. J. Cell Biol. 162, 223-232 (2003).
14. Schmidt, G. and Aktories, K. Bacterial cytotoxins target Rho GTPases. Naturwissenschaften 85, 253-261 (1998).
15. Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M., and Aktories, K. Gln 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature 387, 725-729 (1997).
16. Lerm, M., Schmidt, G., Goehring, U. M., Schirmer, J., and Aktories, K. Identification of the region of Rho involved in substrate recognition by Escherichia coli cytotoxic necrotizing factor 1 (CNF1). J. Biol. Chem. 274, 28999-29004 (1999).
17. Halcox, J.P. and Deanfield, J.E. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 109, 1142-1148 (2004).
18. Laufs, U. and Liao, J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271 (1998).
19. Chica, I., Schneiderhan-Marra, N., Yilmaz, A., Garlichs, C.D., and Goppelt-Struebe, M. Monitoring the cellular effects of HMG-CoA Reductase Inhibitors in vitro and ex vivo. Arterioscler. Thromb. Vasc. Biol. 24, 2046-2050 (2004).
20. Oshiro, N., Fukata, Y, and Kaibuchi, K. Phosphorylation of moesin by Rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J. Biol. Chem. 273, 34663-34666 (1998).
21. Amano, M., Chihara, K., Nakamura, N., Fukata, Y., Yano, T., Shibata, M., Ikebe, M., and Kaibuchi, K. Myosin II activation promotes neurite retraction during the action of Rho and Rho-kinase. Genes Cells 3, 177-188 (1998).
22. 2+ sensitivity in α-toxin permeabilized arterial smooth muscle. Biochem. Biophys. Res. Commun. 157, 677-683 (1988).
23. 2+. J. Biol. Chem. 264, 5229-5342 (1989).
24. 2+-sensitization. Eur. J. Pharmacol. 290, 19-27 (1995).
25. Kimura, K., Ito, M., Amano, M.et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 273, 245-248 (1996).
26. Kureishi, Y., Kobayashi, S., Amano, M., Kimura, K., Kanaide, H., Nakano, T., Kaibuchi, K., and Ito, M. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J. Biol. Chem. 272, 12257-12260 (1997).
27. Uehata, M., Ishizaki, T., Satoh, H. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389, 990-994 (1997).
28. Waf1/Cip1. Nature 394, 295-299 (1998).
29. Laufs, U., Marra, D., Node, K., and Liao, J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27Kip1. J. Biol. Chem. 274, 21926-21931 (1999).
30. 1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272 13-16 (1997).
31. Ridley, A.J. and Hall, A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70, 389-399 (1992).
32. Liu, Y., Suzuki, Y.J., Day, R.M., and Fanburg, B. L. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin. Circ. Res. 95, 579-586 (2004).
33. Kawamura, S., Miyamoto, S., and Brown, J. H. Initiation and transduction of stretch-induced RhoA and Rac1 activation through caveolae: cytoskeletal regulation of ERK translocation. J. Biol. Chem. 278, 31111-31117 (2003).
34. Welsh, C. F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A., and Assoian, R. K. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat. Cell Biol. 3, 950-957 (2001).
35. Roovers, K., Klein, E A., Castagnino, P., and Assoian, R.K. Nuclear translocation of LIM kinase mediates Rho-Rho kinase regulation of cyclin D1 expression. Dev. Cell 5, 273-284 (2003).
36. Krepinsky, J.C., Ingram, A.J., Tang, D., Wu, D., Liu, L., and Scholey, J.W. Nitric oxide inhibits stretch-induced MAPK activation in mesangial cells through RhoA inactivation. J. Am. Soc. Nephrol. 14, 2790-2800 (2003).
37. 1-adrenoceptor in tail artery and aorta from spontaneously hypertensive and Wistar-Kyoto rats. J. Cardiovasc. Pharmacol. 22, 191-197 (1993).
38. 1-adrenoceptor-stimulated contraction in SHR caudal artery. Am. J. Physiol. 250, C275-C282 (1986 ).
39. 2+ sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. J. Clin. Invest. 94, 1397-1403 (1994).
40. Chrissolis, S. and Sobey, C.G. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension. Circ. Res. 88, 774-779 (2001).
41. Hsieh, C.-C. and Lau, Y-T. Migration of vascular smooth muscle cells is enhanced in cultures derived from spontaneously hypertensive rat. Pflugers Arch. 435, 286-292 (1998).
42. Isogai, N., Fujii, S., Tsukahara, T., and Kamiishi, H. Effect of hypertension on arterial structure and wound repair at the microvascular anastamosis site using stroke-prone spontaneously hypertensive rats (SHRSP). Microsurgery 14, 501-507 (1993).
43. Paquet, J.-L., Baudouin-Legros, M., Brunelle, G., and Meyer, P. Angiotensin II-induced proliferation of aortic myocytes in spontaneously hypertensive rats. J. Hypertens. 8, 565-572 (1990).
44. Morton, C., Baines, R., Masood, I., Ng, L., and Boarder, M.R. Stimulation of two vascular smooth muscle-derived cell lines by angiotensin II: Differential second messenger responses leading to mitogenesis. Br. J. Pharmacol. 115, 361-367 (1995).
45. Weber, M.A. Translating data on anti hypertensive drugs into clinical practice. American J. Hypertens. 11, 89S-94S (1998).
46. Turner, S.T. and Boerwinkle, E. Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics. 4, 53-65 (2003).
47. Schiffrin, E. L. Beyond blood pressure: the endothelium and atherosclerosis progression. Am. J. Hypertens. 15, 115S-122S (2002).
48. Kip1 expression in the vasculature of hypertensive rats. Circ. Res. 89, 488-495 (2001).
49. Seko, T., Ito, M., Kureishi, Y., Okamoto, R., Moriki, N., Onishi, K., Isaka, N., Hartshorne, D. J., and Nakano, T. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92, 411-418 (2003).
50. Moriki, N., Ito, M., Seko, T. et al. RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Hypertens. Res. 27, 263-270 (2004).
51. Massey, A. R., Miao, L., Smith, B.N., Liu, J., Kusaka, I., Zhang, J.H., and Tang, J. Increased RhoA translocation in renal cortex of diabetic rats. Life Sci. 72, 2943-2952 (2003).
52. Miao, L., Calvert, J.W., Tang, J., and Zhang, J.H. Upregulation of small GTPase RhoA in the basilar artery from diabetic (mellitus) rats. Life Sci. 71, 1175-1185 (2002).
53. Martin, W., Villani, G.M., Jothianandan, D., and Furchgott, R.F. Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J. Pharmacol. Exp. Ther. 232, 708-716 (1985).
54. Ignarro, L. J., Buga, G.M., Wood, K.S., Byrns, R.E., and Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 84, 9265-9269 (1987).
55. John, S. and Schmieder, R.E. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J. Hypertens. 18, 363-374 (2000).
56. Chou, T.C., Yen, M.H., and Li, C.Y. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 31, 643-648 (1998).
57. Huang, P.L., Huang, Z., Mashimo, H., Bloch, K.D., Moskowitz, M.A., Bevan, J.A., and Fishman, M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239-242 (1995).
58. Lin, K.F., Chao, L., and Chao, J. Prolonged reduction of high blood pressure with human nitric oxide synthase gene delivery. Hypertension 30, 307-313 (1997).
59. Chen, H., Ikeda, U., Shimpo, M., Ikeda, M., Minota, S., and Shimada, K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36, 923-928 (2000).
60. Muniyappa, R., Xu, R., Ram, J.L, and Sowers, J.R. Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am. J. Physiol. 278, H1762-H1768 (2000).
61. Wolfrum, S., Dendorfer, A., Rikitake, Y., Stalker, T.J., Gong, Y., Scalia, R., Dominiak, P., and Lioa, J.K. Inhibition of Rho-kinase leads to a rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arteroslcer. Thromb. Vasc. Biol. 24, 1842-1847 (2004).
62. Sawada, N., Itoh, H., Yamashita, J. et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem. Biophys. Res. Commun. 280, 798-805 (2001).
63. Gohla, A., Schultz, G., and Offermanns, S. Role for G12/G13 in agonist-imduce vascular smooth muscle cell contraction. Circ. Res. 87, 221-227 (2000).
64. 2+ sensitization of contraction in vascular smooth muscle. J. Biol. Chem. 275, 21722-21729 (2000).
65. Gudi, T., Chen, J.C., Casteel, D.E., Seasholtz, T.M., Boss, G.R., and Pilz, R.B. cGMP-dependent protein kinase inhibits serum-response element-dependent transcription by inhibiting rho activation and functions. J. Biol. Chem. 277, 37382-37393 (2002).
66. Barbato, J. E. and Tzeng, E. Nitric oxide and arterial disease. J. Vasc. Surg. 40, 187-193 (2004).
67. Suzuki, J., Izawa, A., and Isobe, M. Anti-vascular cell adhesion molecule-1 and anti-very late antigen-4 monoclonal antibodies inhibit neointimal hyperplasia in the murine model of arterial injury. Acta. Cardiol. 59, 147-152 (2004).
68. Negoro, N., Hoshiga, M., Seto, M. et al. The kinase inhibitor fasudil (HA-1077) reduces intimal hyperplasia through inhibiting migration and enhancing cell loss of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 262, 211-215 (1999).
69. Sawada, N., Itoh, H., Ueyama, K. et al. Inhibition of Rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 101, 2030-2033 (2000 ).
70. Shibata, R., Kai, H., Seki, Y., Kato, S., Morimatsu, M., Kaibuchi, K., and Imaizumi, T. Role of Rho-Associated Kinase in Neointima Formation After Vascular Injury. Circulation 103, 284-289 (2001).
71. Matsumoto, Y., Uwatoku, T., Oi, K. et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: Involvement of multiple mechanisms. Arterioscler. Thromb. Vasc. Biol. 24, 181-186 (2004).
72. Eto, Y., Shimokawa, H., Hiroki, J. et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am. J. Physiol. Heart. Circ. Physiol. 278, H1744-H1750 (2000).
73. Mallat, Z., Gojova, A., Sauzeau, V. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ. Res. 93, 884-888 (2003).
74. Kataoka, C., Egashira, K., Inoue, S. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 39, 245-250 (2002).
75. Herdeg, C., Fitzke, M., Oberhoff, M., Baumbach, A., Schroeder, S., and Karsch, K.R. Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. Int. J. Cardiol. 91, 59-69 (2003).
76. Ni, W., Egashira, K., Kataoka, C., Kitamoto, S., Koyanagi, M., Inoue, S., and Takeshita, A. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res. 89 , 415-421 (2001).
77. Sagi, S.A., Seasholtz, T.M., Kobiashvilla, M., Wilson, B.A., Toksoz, D., and Brown, J.H. Physical and functional interactions of Gaq with Rho and its exchange factors. J. Biol. Chem. 276, 15445-15452 (2001).
78. Seasholtz, T.M., Radeff-Huang, J., Sagi, S.A., Matteo, R.G., Weems, J.M., Stoudt, A., Buckmaster, C., Feramisco, J., and Brown, J.H. Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2. J. Neurochem. 91, 501-12 (2004).
79. 3. Science 280, 2112-2114 (1998).
80. Fukuhara, S., Murga, C., Zohar, M., Igishi, T., and Gutkind, J.S. A novel PDZ domain containing guanine nucleotide exchange factor links heterotrimeric G proteins to Rho. J. Biol. Chem. 274, 5868-5879 (1999).
81. 12 family to Rho. FEBS Lett. 485, 183-188 (2000).
82. Jin, S. and Exton, J. H. Activation of RhoA by association of Galpha(13) with Dbl. Biochem. Biophys. Res. Commun. 277, 718-721 (2000).
83. 2+ sensitization of myosin light chain20 phosphorylation. Mol. Pharmacol. 63, 714-721 (2003).
84. Nwariaku, F.E., Rothenbach, P., Liu, Z., Zhu, X., Turnage, R.H., and Terada, L.S. Rho inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J. Appl. Physiol. 95 1889-1895 (2003).
85. Nubel, T., Dippold, W., Kleinert, H., Kaina, B., and Fritz, G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J. 18, 140-142 (2004).
86. Xia, P., Wang, L., Gamble, J.R., and Vadas, M.A. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J. Biol. Chem. 274, 34499-34505 (1999).
87. Chen, X.-L., Grey, J.Y., Thomas, S., Qui, F.-H., Medford, R.M., Wasserman, M.A., and Kunsch, C. Sphringosine kinase-1 mediates TNF-α-induced MCP-1 gene expression in endothelial cells: upregulation by oscillatory flow. Am. J. Physiol. 287, H1452-H1458 (2004).
88. Singh, R., Wang, B., Shirvaikar, A., Khan, S., Kamat, S., Schelling, J.R., Konieczkowski, M., and Sedor, J.R. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J. Clin. Invest. 103, 1561-1570 (1999).
89. John, G.R., Chen, L., Rivieccio, M.A., Melendez-Vasquez, C.V., Hartley, A., and Brosnan, C.F. Interleukin-1beta induces a reactive astroglial phenotype via deactivation of the Rho GTPase-Rock axis. J. Neurosci. 24, 2837-2845 (2004).
90. Miller, Y.I., Viriyakosol, S., Binder, C.J., Feramisco, J. R., Kirkland, T.N., and Witztum, J.L. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J. Biol. Chem. 278, 1561-1568 (2003).
91. Auge, N., Nikolova-Karakashian, M., Carpentier, S., Parthasarathy, S., Negre-Salvayre, A., Salvayre, R., Merrill, A. H., Jr., and Levade, T. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J. Biol. Chem. 274, 21533-21538 (1999).
92. Schaefer, C.A., Kuhlmann, C.R., Gast, C. et al. Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells. Vascul. Pharmacol. 41, 67-73 (2004).
93. Galle, J., Mameghani, A., Bolz, S.S. et al. Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J. Am. Soc. Nephrol. 14 1471-1479 (2003).
94. Napoli, C., Lerman, L.O., de Nigris, F., Loscalzo, J., and Ignarro, L.J. Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells. J. Am. Coll. Cardiol. 40, 1515-1522 (2002).
95. Siess, W., Zangl, K. J., Essler, M., Bauer, M., Brandl, R., Corrinth, C., Bittman, R., Tigyi, G., and Aepfelbacher, M. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc. Natl. Acad. Sci. U.S.A. 96, 6931-6936 (1999).
96. Auge, N., Garcia, V., Maupas-Schwalm, F., Levade, T., Salvayre, R., and Negre-Salvayre, A. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler. Thromb. Vasc. Bio.l 22, 1990-1995 (2002).
97. Auge, N., Andrieu, N., Negre-Salvayre, A., Thiers, J.C., Levade, T., and Salvayre, R. The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J. Biol. Chem. 271, 19251-19255 (1996).
98. Senftleben, U. and Karin, M. The JKK/NF-kappaB pathway. Crit. Care. Med. 30, S18-S26 (2002).
99. Li, X. and Stark, G. R. NFkappaB-dependent signaling pathways. Exp. Hematol. 30, 285-296 (2002).
100. Pan, Z.K., Ye, R.D., Christiansen, S.C., Jagels, M.A., Bokoch, G.M., and Zuraw, B.L. Role of the Rho GTPase in bradykinin-stimulated Nuclear Factor-kB activation and IL-1β gene expression in cultured human epithelial cells. J. Immunol. 160 3038-3045 (1998).
101. Siehler, S., Wang, Y., Fan, X., Windh, R. T., and Manning, D. R. Sphingosine 1-phosphate activates nuclear factor-kappa B through Edg receptors. Activation through Edg-3 and Edg-5, but not Edg-1, in human embryonic kidney 293 cells. J. Biol. Chem. 276, 48733-48739 (2001).
102. Shepard, L.W., Yang, M., Xie, P., Browning, D.D., Voyno-Yasenetskaya, T., Kozasa, T., and Ye, R.D. Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA. J. Biol. Chem. 276, 45979-45987 (2001).
103. Chen, L.Y., Ptasznik, A., and Pan, Z.K. RhoA and Rac1 signals in fMLP-induced NF-kappaB activation in human blood monocytes. Biochem. Biophys. Res. Commun. 319, 629-635 (2004).
104. Chen, L.Y., Zuraw, B.L., Ye, R.D., and Pan, Z.K. A Rho exchange factor mediates fMet-Leu-Phe-induced NF-kappaB activation in human peripheral blood monocytes. J. Biol. Chem. 279, 7208-7212 (2004).
105. Hippenstiel, S., Schmeck, B., Seybold, J., Krull, M., Eichel-Streiber, C., and Suttorp, N. Reduction of tumor necrosis factor-alpha (TNF-alpha) related nuclear factor-kappaB (NF-kappaB) translocation but not inhibitor kappa-B (Ikappa-B)-degradation by Rho protein inhibition in human endothelial cells. Biochem. Pharmacol. 64, 971-977 (2002).
106. Segain, J.P., Raingeard, d. I.B., Sauzeau, V. et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: Evidence in Crohn's disease and experimental colitis. Gastroenterology 124, 1180-1187 (2003).
107. Wang, Z., Castresana, M.R., Detmer, K., and Newman, W.H. An IkappaB-alpha mutant inhibits cytokine gene expression and proliferation in human vascular smooth muscle cells. J. Surg. Res. 102, 198-206 (2002).
108. Zuckerbraun, B.S., McCloskey, C.A., Mahidhara, R.S., Kim, P.K., Taylor, B.S., and Tzeng, E. Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation. J. Vasc. Surg. 38, 812-819 (2003).